Ron D. Jachimowicz
YOU?
Author Swipe
Generation of faithful autochthonous mouse models of Mantle Cell Lymphoma Open
Introduction: MantleCell Lymphoma (MCL) is characterized by the translocation t(11;14) resulting in overexpression of Cyclin D1. Other frequently observed alterations include SOX11 overexpression (90% of patients), and aberrations of ATM (…
View article: Comprehensive analysis of bridging to CAR-T cell therapy in large B-cell lymphoma with conventional treatment or the CD3xCD20 bispecific antibody glofitamab
Comprehensive analysis of bridging to CAR-T cell therapy in large B-cell lymphoma with conventional treatment or the CD3xCD20 bispecific antibody glofitamab Open
Abstract Introduction Despite evidence supporting the importance of remission prior to CAR-T therapy in relapsed/refractory large B-cell lymphoma (rrLBCL), standardized bridging strategies are lacking. Glofitamab, a CD3/CD20 bispecific ant…
View article: Functional synapses between neurons and small cell lung cancer
Functional synapses between neurons and small cell lung cancer Open
Small cell lung cancer (SCLC) is a highly aggressive type of lung cancer, characterized by rapid proliferation, early metastatic spread, frequent early relapse and a high mortality rate 1–3 . Recent evidence has suggested that innervation …
Establishment and Characterization of a <i>CCND1</i> -Rearranged Non-Mantle Cell Lymphoma Cell Line and Patient-Derived Xenograft Model Open
The pathobiology of aggressive B-cell lymphomas with CCND1 rearrangements, distinct from Mantle Cell Lymphoma (MCL), presents a significant clinical challenge. These lymphomas are often difficult to diagnose and demonstrate resistance to s…
View article: CSF1R+ myeloid-monocytic cells drive CAR-T cell resistance in aggressive B cell lymphoma
CSF1R+ myeloid-monocytic cells drive CAR-T cell resistance in aggressive B cell lymphoma Open
Despite the improvement, approximately 60% of patients with relapsed or refractory (r/r) aggressive B cell lymphoma (B-NHL) do not achieve durable benefit from CAR-T cell therapy. To elucidate factors associated with CAR-T therapy resistan…
Starvation-induced metabolic rewiring affects mTORC1 composition in vivo Open
Lysosomes play a crucial role in metabolic adaptation to starvation, but detailed in vivo studies are scarce. Therefore, we investigated the changes of the proteome of liver lysosomes in mice starved short-term for 6h or long-term for 24h.…
View article: Targeting Lymphoma Associated Myeloid-Monocytic Cells through CSF1R Blockade Enhances CAR-T Cell Response in Aggressive B Cell Lymphoma
Targeting Lymphoma Associated Myeloid-Monocytic Cells through CSF1R Blockade Enhances CAR-T Cell Response in Aggressive B Cell Lymphoma Open
Introduction: Chimeric antigen receptor (CAR) T cell therapy has substantially improved the outcome of patients suffering from relapsed and/or refractory (r/r) aggressive B cell lymphoma. However, around 60% of patients do not show long-te…
An inducible <i>Cd79b</i> mutation confers ibrutinib sensitivity in mouse models of <i>Myd88</i>-driven diffuse large B-cell lymphoma Open
Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive lymphoma and constitutes a highly heterogenous disease. Recent comprehensive genomic profiling revealed the identity of numerous molecularly defined DLBCL subtypes, includ…
Mouse models of diffuse large B cell lymphoma Open
Diffuse large B cell lymphoma (DLBCL) is a genetically highly heterogeneous disease. Yet, to date, the vast majority of patients receive standardized frontline chemo-immune-therapy consisting of an anthracycline backbone. Using these regim…
An <i>In Vivo PiggyBac</i> Insertional Mutagenesis Screen Reveals Oncogenic Lesions Cooperating with <i>Myd88 L265P</i> Open
Diffuse large B cell lymphoma (DLBCL) is the most common Non-Hodgkin lymphoma and originates from transformed germinal center-experienced B cells. Traditionally, DLBCL has been divided into two subtypes, depending on whether the transcript…
Optical genome mapping identifies structural variants in potentially new cancer predisposition candidate genes in pediatric cancer patients Open
Genetic predisposition is one of the major risk factors for pediatric cancer, with ~10% of children being carriers of a predisposing germline alteration. It is likely that this is the tip of the iceberg and many children are underdiagnosed…
Differential ibrutinib sensitivity in Cd79b‐mutant and wildtype subtypes of a novel Myd88‐driven DLBCL mouse model Open
Introduction: Recent efforts have established distinct subtypes of DLBCL by clustering cases based on their mutational profiles. Mutations associated with the MCD/C5 cluster include MYD88 p.L265P, CD79B p.Y196X and BCL2 amplifications. Sev…
Table S1 from Distinct Genetically Determined Origins of <i>Myd88</i>/<i>BCL2</i>-Driven Aggressive Lymphoma Rationalize Targeted Therapeutic Intervention Strategies Open
Table S1 contains the p values of comparisons of the V gene usage in non-malignant GC B cells between the individual genotypes. These comparisons were done on the family, gene and allele level. V usage was compared for all BCR sequences as…
Table S6 from Distinct Genetically Determined Origins of <i>Myd88</i>/<i>BCL2</i>-Driven Aggressive Lymphoma Rationalize Targeted Therapeutic Intervention Strategies Open
Table S6 contains clinical parameters and sequencing results of human DLBCL samples.
Table S2 from Distinct Genetically Determined Origins of <i>Myd88</i>/<i>BCL2</i>-Driven Aggressive Lymphoma Rationalize Targeted Therapeutic Intervention Strategies Open
Table S2 contains a summary of the B cell receptor sequencing data of lymphoma samples. It includes 1) an overview of the investigated samples, 2) a list of characteristics of the dominant clone of each lymphoma sample, 3) a list comparing…
Supplementary Figures S1 to S12 from Distinct Genetically Determined Origins of <i>Myd88</i>/<i>BCL2</i>-Driven Aggressive Lymphoma Rationalize Targeted Therapeutic Intervention Strategies Open
This file contains the Supplementary Figures S1 to S12.
Table S2 from Distinct Genetically Determined Origins of <i>Myd88</i>/<i>BCL2</i>-Driven Aggressive Lymphoma Rationalize Targeted Therapeutic Intervention Strategies Open
Table S2 contains a summary of the B cell receptor sequencing data of lymphoma samples. It includes 1) an overview of the investigated samples, 2) a list of characteristics of the dominant clone of each lymphoma sample, 3) a list comparing…
Data from Distinct Genetically Determined Origins of <i>Myd88</i>/<i>BCL2</i>-Driven Aggressive Lymphoma Rationalize Targeted Therapeutic Intervention Strategies Open
Genomic profiling revealed the identity of at least 5 subtypes of diffuse large B-cell lymphoma (DLBCL), including the MCD/C5 cluster characterized by aberrations in MYD88, BCL2, PRDM1, and/or SPIB. We generated mouse models harboring B ce…
Table S3 from Distinct Genetically Determined Origins of <i>Myd88</i>/<i>BCL2</i>-Driven Aggressive Lymphoma Rationalize Targeted Therapeutic Intervention Strategies Open
Table S3 contains B cell receptor repertoire sequencing data and lists the individual sublcones of the dominant clones of MBC, SMBC and PPMBC lymphomas.
Table S5 from Distinct Genetically Determined Origins of <i>Myd88</i>/<i>BCL2</i>-Driven Aggressive Lymphoma Rationalize Targeted Therapeutic Intervention Strategies Open
Table S5 contains statistical values of gene set enrichment analyses of the KEGG, BIOCARTA and HALLMARK gene set collections.
Table S6 from Distinct Genetically Determined Origins of <i>Myd88</i>/<i>BCL2</i>-Driven Aggressive Lymphoma Rationalize Targeted Therapeutic Intervention Strategies Open
Table S6 contains clinical parameters and sequencing results of human DLBCL samples.
Table S1 from Distinct Genetically Determined Origins of <i>Myd88</i>/<i>BCL2</i>-Driven Aggressive Lymphoma Rationalize Targeted Therapeutic Intervention Strategies Open
Table S1 contains the p values of comparisons of the V gene usage in non-malignant GC B cells between the individual genotypes. These comparisons were done on the family, gene and allele level. V usage was compared for all BCR sequences as…
Table S5 from Distinct Genetically Determined Origins of <i>Myd88</i>/<i>BCL2</i>-Driven Aggressive Lymphoma Rationalize Targeted Therapeutic Intervention Strategies Open
Table S5 contains statistical values of gene set enrichment analyses of the KEGG, BIOCARTA and HALLMARK gene set collections.